TABLE 4.
Performance of Espline HTLV-I/II with LIA indeterminate provirus-positive samples e
| No. | CLIA, S/CO a | ECLIA, S/CO | CLEIA b , COI c | PA | IC | LIA | LIA band intensity | PCR | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| p19 | p24 | gp46 | gp21 | p19-I | gp46-I | gp46-II | ||||||||
| 1 | 34.6 | 16.6 | NT d | + | + | Indeterminate | − | − | − | 2+ | − | − | − | + |
| 2 | 36.6 | 12.3 | NT | + | + | Indeterminate | − | − | − | 2+ | − | − | − | + |
| 3 | 11.0 | 4.4 | NT | + | + | Indeterminate | − | − | − | 2+ | − | − | − | + |
| 4 | 2.1 | 1.3 | NT | − | + | Indeterminate | − | − | − | 2+ | − | − | − | + |
| 5 | 3.5 | 11.6 | NT | + | + | Indeterminate | − | − | − | ± | − | − | − | + |
| 6 | 3.7 | 4.4 | NT | − | + | Indeterminate | − | − | − | ± | − | − | − | + |
| 7 | 2.2 | 4.2 | NT | + | − | Indeterminate | − | − | − | ± | − | − | − | + |
| 8 | 1.9 | 99.6 | NT | − | − | Indeterminate | − | − | − | 1+ | − | − | − | + |
| 9 | 4.2 | 44.5 | NT | + | + | Indeterminate | − | − | − | 2+ | − | − | − | + |
| 10 | 21.1 | 38.8 | NT | + | + | Indeterminate | − | − | − | 2+ | − | − | − | + |
| 11 | 7.61 | NT | NT | + | + | Indeterminate | 2+ | 2+ | − | − | − | − | − | + |
| 12 | 0.16 | NT | 2.7 | + | − | Indeterminate | 1+ | ± | − | − | − | − | − | + |
| 13 | NT | NT | 2.3 | + | + | Indeterminate | − | − | − | 1+ | − | − | − | + |
a
S/CO, signal-to-cutoff ratio.
b
CLEIA, Lumipulse Presto HTLV-I.
c
COI, cutoff index.
d
NT, not tested.
e
Underlined numbers are scores that were applied at the antibody screening test.